<DOC>
	<DOCNO>NCT02964910</DOCNO>
	<brief_summary>This phase IV clinical study design evaluate immunogenicity safety recombinant Hepatitis E vaccine ( Hecolin® ) , manufacture Xiamen Innovax Biotech CO. , LTD. , chronic Hepatitis B patient clinical stability age 30 year age enrollment . The study volunteer receive 3 dos Hecolin® administer intramuscularly accord 0-1-6 month schedule .</brief_summary>
	<brief_title>A Phase Ⅳ Clinical Trial Recombinant Hepatitis E Vaccine ( Escherichia Coli ) ( Chronic Hepatitis B Patients )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria ( volunteer ) : 1 . Aged 30 year old day enrollment 2 . Axillary temperature 37.0 ℃ . 3 . No administration HEV vaccine study 4 . Judged healthy eligible vaccination investigator selfreported medical history physical examination . 5 . Able understand study information willing comply study requirement . 6 . Willing participate study sign inform consent form . 7 . Negative serological marker hepatitis E Inclusion Criteria ( experiment group ) : 1 . ALT &lt; 1.5×ULN 2 . No spleen swell , cirrhosis hepatocellular carcinoma Inclusion Criteria ( control group ) : 1 . HBsAg ( ) 1 . With clinical evidence malignant tumor 2 . History severe cardiocerebrovascular disease 3 . Administration hepatotoxicity drug study 4 . Pregnancy , breastfeed plan pregnant 7 month later 5 . Participated clinical trial study period . 6 . Use investigational product nonregistered product ( drug vaccine ) within 30 day precede first dose study vaccine plan use study period . 7 . Received immunosuppressed , immunoregulation therapy corticosteroid systemic therapy 14 day 6 month entry , except local treatment . 8 . Administration immunoglobulin blood product within 3 month precede first dose study vaccine , plan use study period . 9 . Administration inactivate vaccine within 14 day precede first dose study attenuate live vaccine within 21 day precede first dose study . 10 . Had fever ( axillary temperature 38°C ) within 3 day acute illness require systemic antibiotic antiviral treatment within 5 day vaccination . 11 . Immunodeficiency ( HIV carrier ) , primary disease important organ , malignant tumor , immune disease ( systemic lupus erythematosus , arthritis pauperum , splenectomy functional asplenia disease might affect immune response ) . 12 . History allergic disease history serious adverse event occur vaccination , i.e. , allergy , urticaria , dyspnea , angioneurotic edema abdominal pain . 13 . Allergic history component vaccine . 14 . Asthma need emergency treatment , hospitalization , oral intravenous corticosteroid keep stable past two year . 15 . Combining another severe internal medicine disease ( severe hypertension , cardiopathy , diabetes hyperthyroidism ) 16 . Anomal coagulation function coagulopathy diagnose doctor 17 . Epilepsy ( include alcohol epilepsy within 3 year prior abstinence simple epilepsy without cure within 3 year prior study ) 18 . Anomal psychology mind affect individual 's ability obey study requie 19 . Other medical , psychological , social occupational factor , accord investigator ' judgment , might affect individual 's ability obey protocol sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis E</keyword>
</DOC>